Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement

Herrmann, J. et al. (2022) Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. European Heart Journal, 43(4), pp. 280-299. (doi: 10.1093/eurheartj/ehab674) (PMID:34904661) (PMCID:PMC8803367)

[img] Text
251609.pdf - Accepted Version

1MB

Abstract

The discipline of Cardio-Oncology has seen tremendous growth over the past decade. It is devoted to the cardiovascular (CV) care of the cancer patient, especially to the mitigation and management of CV complications or toxicities of cancer therapies, which can have profound implications on prognosis. To that effect, many studies have assessed CV toxicities in patients undergoing various types of cancer therapies; however, direct comparisons have proven difficult due to lack of uniformity in CV toxicity endpoints. Similarly, in clinical practice, there can be substantial differences in the understanding of what constitutes CV toxicity, which can lead to significant variation in patient management and outcomes. This document addresses these issues and provides consensus definitions for the most commonly reported CV toxicities, including cardiomyopathy/heart failure and myocarditis, vascular toxicity, and hypertension, as well as arrhythmias and QTc prolongation. The current document reflects a harmonizing review of the current landscape in CV toxicities and the definitions used to define these. This consensus effort aims to provide a structure for definitions of CV toxicity in the clinic and for future research. It will be important to link the definitions outlined herein to outcomes in clinical practice and CV endpoints in clinical trials. It should facilitate communication across various disciplines to improve clinical outcomes for cancer patients with CV diseases.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Lang, Professor Ninian
Authors: Herrmann, J., Lenihan, D., Armenian, S., Barac, A., Blaes, A., Cardinale, D., Carver, J., Dent, S., Ky, B., Lyon, A. R., López-Fernández, T., Fradley, M. G., Ganatra, S., Curigliano, G., Mitchell, J. D., Minotti, G., Lang, N. N., Liu, J. E., Neilan, T. G., Nohria, A., O'Quinn, R., Pusic, I., Porter, C., Reynolds, K. L., Ruddy, K. J., Thavendiranathan, P., and Valent, P.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:European Heart Journal
Publisher:Oxford University Press
ISSN:0195-668X
ISSN (Online):1522-9645
Published Online:14 December 2021
Copyright Holders:Copyright © 2021 The Authors
First Published:First published in European Heart Journal 43(4): 280-299
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
306137MARKERS AND MEDIATORS OF ANGIOGENESIS INHIBITOR-INDUCED VASCULAR AND MYOCARDIAL TOXICITY: A Prospective Study in Patients with CancerNinian LangBritish Heart Foundation (BHF)PG/19/64/34434CAMS - Cardiovascular Science